Liu, C., Lou, W., Zhu, Y., Yang, J.C., Nadiminty, N., et al. (2015) Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Research, 75, 1413-1422.
https://doi.org/10.1158/0008-5472.CAN-14-3080

has been cited by the following article:

• TITLE: Darwinian Selection in Prostate Cancer and Medical Treatment

  AUTHORS: Chunjiao Song

  KEYWORDS: Prostate Cancer, Androgen Receptor, Tumor Microenvironment, Darwinian Selection

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.8 No.6, June 16, 2017

  ABSTRACT: Organisms evolved into different species to adapt to the environment according to the laws of Darwinian evolution. In a single life, prostate cancer cells can also evolve into tumor stem cells to adapt to the microenvironment, such as different chemotherapeutic drugs. These cancer cells become an unrestricted growth group relatively independent of the individual. The present review attempts to establish evidence that prostate cancer cells may survive by hormonotherapy and chemotherapy by gene amplification, mutation, and alternative splicing. Simultaneously, novel treatment strategies have been cited and evaluated, avoiding the resistance mechanisms.